Safinamide – A New Therapeutic Option to Address Motor Symptoms and Motor Complications in Mid- to Late-stage Parkinson’s Disease
Overview of Parkinson’s disease Epidemiology Parkinson’s disease (PD) is a common, chronic and progressive neurological condition. It is estimated to affect 100–180 people per 100,000 of the population and has an annual incidence of 4–20 per 100,000 people.1 The prevalence of PD rises sharply with age, from a mean of 41 per 100,000 in those […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!